» Articles » PMID: 39164066

Positive Feedback Loop PU.1-IL9 in Th9 Promotes Rheumatoid Arthritis Development

Abstract

Objectives: T helper 9 (Th9) cells are recognised for their characteristic expression of the transcription factor PU.1 and production of interleukin-9 (IL-9), which has been implicated in various autoimmune diseases. However, its precise relationship with rheumatoid arthritis (RA) pathogenesis needs to be further clarified.

Methods: The expression levels of PU.1 and IL-9 in patients with RA were determined by ELISA, western blotting (WB) and immunohistochemical staining. PU.1-T cell-conditional knockout (KO) mice, IL-9 KO and IL-9R KO mice were used to establish collagen antibody-induced arthritis (CAIA), respectively. The inhibitor of PU.1 and IL-9 blocking antibody was used in collagen-induced arthritis (CIA). In an in vitro study, the effects of IL-9 were investigated using siRNAs and IL-9 recombinant proteins. Finally, the underlying mechanisms were further investigated by luciferase reporter analysis, WB and Chip-qPCR.

Results: The upregulation of IL-9 expression in patients with RA exhibited a positive correlation with clinical markers. Using CAIA and CIA model, we demonstrated that interventions targeting PU.1 and IL-9 substantially mitigated the inflammatory phenotype. Furthermore, in vitro assays provided the proinflammatory role of IL-9, particularly in the hyperactivation of macrophages and fibroblast-like synoviocytes. Mechanistically, we uncovered that PU.1 and IL-9 form a positive feedback loop in RA: (1) PU.1 directly binds to the IL-9 promoter, activating its transcription and (2) Th9-derived IL-9 induces PU.1 via the IL-9R-JAK1/STAT3 pathway.

Conclusions: These results support that the PU.1-IL-9 axis forms a positive loop in Th9 dysregulation of RA. Targeting this signalling axis presents a potential target approach for treating RA.

Citing Articles

Targeting γc family cytokines with biologics: current status and future prospects.

Bick F, Blanchetot C, Lambrecht B, Schuijs M MAbs. 2025; 17(1):2468312.

PMID: 39967341 PMC: 11845063. DOI: 10.1080/19420862.2025.2468312.

References
1.
Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, La Manna M . Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2015; 54(12):2264-72. DOI: 10.1093/rheumatology/kev252. View

2.
Bheda A, Yue W, Gullapalli A, Shackelford J, Pagano J . PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells. Leuk Lymphoma. 2011; 52(7):1336-47. PMC: 4435811. DOI: 10.3109/10428194.2011.562571. View

3.
Lee J, Lozano-Ruiz B, Yang F, Fan D, Shen L, Gonzalez-Navajas J . The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. Front Immunol. 2021; 12:625667. PMC: 7994325. DOI: 10.3389/fimmu.2021.625667. View

4.
Heim J, Almanzar G, Schmalzing M, Gernert M, Tony H, Prelog M . Induction of IL-9 in Peripheral Lymphocytes of Rheumatoid Arthritis Patients and Healthy Donors by Th17-Inducing Cytokine Conditions. Front Immunol. 2021; 12:668095. PMC: 8117786. DOI: 10.3389/fimmu.2021.668095. View

5.
Lloberas J, Soler C, Celada A . The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages. Immunol Today. 1999; 20(4):184-9. DOI: 10.1016/s0167-5699(99)01442-5. View